Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
November 04 2021 - 8:30AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced that Dr. Steven O’Day, Chief Medical
Officer at Agenus and Dr. Manuel Hidalgo, Chief of the Division of
Hematology and Medical Oncology at Weill Cornell Medicine and New
York-Presbyterian/Weill Cornell Medical Center, will participate in
a webcast hosted by Dr. Matt Phipps, biotechnology analyst at
William Blair on Friday, November 12, 2021 at 12:00 p.m. ET.
Dr. Steven O’Day and Dr. Manuel Hidalgo will review the updated
Phase 1 clinical trial results for AGEN1181 (Fc-enhanced
anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1),
which will be presented at the Society for Immunotherapy of Cancer
(SITC) 36th Annual Meeting on November 12th, 2021. They will also
discuss the significance of these data and how they may inform the
path forward for continued development.
Registration for the webinar can be done in advance at
https://williamblair.zoom.us/webinar/register/WN_WzxgjO1MRw6dKIWm3nAg-w
A replay will be available after the call for 30 days on the
Events & Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its affiliate MiNK Therapeutics), adjuvants, and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to the use of therapeutic candidates AGEN 1181
and balstilimab, for instance, statements regarding therapeutic
benefit and efficacy, mechanism of action, potency, durability, and
safety profile of the therapeutic candidates, both alone and in
combination with each other and/or other agents; future clinical
and regulatory development plans for AGEN1181 alone and in
combination with other agents, including balstilimab; our ability
to obtain regulatory approval for AGEN1181, alone and in
combination with other agents, including balstilimab, including the
timing (including the possibility of accelerated review) and scope
of any such regulatory approval; and any other statements
containing the words "may," "believes," "expects," "anticipates,"
"hopes," "intends," "plans," "will" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
ContactAgenus Inc.Divya
Vasudevan, PhD781-674-4571divya.vasudevan@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024